FDA escalates Vitruvias Therapeutics thyroid tablet recall to highest risk level
The FDA has upgraded the recall of a 30 mg thyroid tablet lot from Vitruvias Therapeutics to a Class I recall, the agency’s most serious category.
Why it matters
A Class I recall warns that the thyroid tablets could cause serious injury or death, prompting urgent removal from patients.
In this story
FDAClass I recallVitruvias Therapeuticsthyroid tablets30 mgproduct safetyrecall escalation
